These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 18316345)
1. Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines. Julka PK; Doval DC; Gupta S; Rath GK Br J Radiol; 2008 Jun; 81(966):444-9. PubMed ID: 18316345 [TBL] [Abstract][Full Text] [Related]
2. Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Barnacle AM; McHugh K Pediatr Blood Cancer; 2006 Feb; 46(2):127-34. PubMed ID: 16231313 [TBL] [Abstract][Full Text] [Related]
3. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. Mazumdar M; Smith A; Schwartz LH J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836 [TBL] [Abstract][Full Text] [Related]
4. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Liu Y; Litière S; de Vries EG; Sargent D; Shankar L; Bogaerts J; Seymour L Eur J Cancer; 2014 Jan; 50(2):260-6. PubMed ID: 24239447 [TBL] [Abstract][Full Text] [Related]
5. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Watanabe H; Yamamoto S; Kunitoh H; Sekine I; Yamamoto N; Ohe Y; Tamura T; Kodama T; Sugimura K; Saijo N Cancer Sci; 2003 Nov; 94(11):1015-20. PubMed ID: 14611681 [TBL] [Abstract][Full Text] [Related]
7. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Aras M; Erdil TY; Dane F; Gungor S; Ones T; Dede F; Inanir S; Turoglu HT Nucl Med Commun; 2016 Jan; 37(1):9-15. PubMed ID: 26440568 [TBL] [Abstract][Full Text] [Related]
8. Improving accuracy in reporting CT scans of oncology patients: assessing the effect of education and feedback interventions on the application of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Andoh H; McNulty NJ; Lewis PJ Acad Radiol; 2013 Mar; 20(3):351-7. PubMed ID: 23452481 [TBL] [Abstract][Full Text] [Related]
9. Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? McHugh K; Kao S Br J Radiol; 2003 Jul; 76(907):433-6. PubMed ID: 12857700 [No Abstract] [Full Text] [Related]
10. RECIST revisited: a review of validation studies on tumour assessment. Therasse P; Eisenhauer EA; Verweij J Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487 [TBL] [Abstract][Full Text] [Related]
11. [CT evaluation of response to chemotherapy and/or radiotherapy in primary lung cancer: comparison of response evaluation criteria in solid tumors (RECIST) and the WHO criteria, and comparison of both methods with the histological evaluation]. Konishi K; Kuriyama K; Chino S; Isohashi K; Murata M; Tsuda K; Mitani T; Maeda M; Kadota T; Arisawa J Nihon Igaku Hoshasen Gakkai Zasshi; 2004 Jan; 64(1):41-5. PubMed ID: 14994510 [TBL] [Abstract][Full Text] [Related]
12. [Measurement of tumour response to cancer treatment: morphologic imaging role]. Ollivier L; Leclère J; Thiesse P; Di Stefano D; Vincent C Bull Cancer; 2007 Feb; 94(2):171-7. PubMed ID: 17337386 [TBL] [Abstract][Full Text] [Related]
13. RECIST - learning from the past to build the future. Litière S; Collette S; de Vries EG; Seymour L; Bogaerts J Nat Rev Clin Oncol; 2017 Mar; 14(3):187-192. PubMed ID: 27995946 [TBL] [Abstract][Full Text] [Related]
14. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer. Kim HS; Kim JH; Yang I Lung Cancer; 2014 Sep; 85(3):385-9. PubMed ID: 25074845 [TBL] [Abstract][Full Text] [Related]
15. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation? Liu Q; Li A; Sun S; Luo R; Chen F J BUON; 2014; 19(2):398-405. PubMed ID: 24965398 [TBL] [Abstract][Full Text] [Related]
16. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. Watanabe H; Okada M; Kaji Y; Satouchi M; Sato Y; Yamabe Y; Onaya H; Endo M; Sone M; Arai Y Gan To Kagaku Ryoho; 2009 Dec; 36(13):2495-501. PubMed ID: 20009446 [TBL] [Abstract][Full Text] [Related]
17. Tumor response evaluation in oncology: current update. Shanbhogue AK; Karnad AB; Prasad SR J Comput Assist Tomogr; 2010 Jul; 34(4):479-84. PubMed ID: 20657213 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the response to therapy of neoplastic lesions. Bellomi M; Preda L Radiol Med; 2004; 107(5-6):450-8. PubMed ID: 15195007 [TBL] [Abstract][Full Text] [Related]
19. Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer. Kim HS; Kim JW; Kim JH; Choi DR; Han AR; Kim MJ; Kim BC; Zang DY Oncology; 2015; 88(2):69-75. PubMed ID: 25277674 [TBL] [Abstract][Full Text] [Related]
20. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Seymour L; Bogaerts J; Perrone A; Ford R; Schwartz LH; Mandrekar S; Lin NU; Litière S; Dancey J; Chen A; Hodi FS; Therasse P; Hoekstra OS; Shankar LK; Wolchok JD; Ballinger M; Caramella C; de Vries EGE; Lancet Oncol; 2017 Mar; 18(3):e143-e152. PubMed ID: 28271869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]